KCM
PACB icon

KRS Capital Management’s Pacific Biosciences PACB Stock Holding History

KRS Capital Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,500
Closed -$71K – 276
2021
Q4 		$71K Buy
+3,500
New +$84.5K 0.06% 206

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

KRS Capital Management's PACB Position: Q1 2022 in Review

KRS Capital Management sold out of Pacific Biosciences (PACB) in Q1 2022, closing a stake of 3,500 shares — an estimated $71K sold.

KRS Capital Management first reported a position in PACB in Q4 2021 and held it in 1 quarter. The position peaked at $71K in Q4 2021. 250 funds tracked by Wall St. Rank hold PACB as of Q1 2022.

  • KRS Capital Management reported no remaining Pacific Biosciences position as of Q1 2022 after selling out during the quarter.
  • KRS Capital Management sold 3,500 Pacific Biosciences shares in Q1 2022, an estimated $71K.
  • KRS Capital Management first reported a position in Pacific Biosciences in Q4 2021 and held it in 1 quarter.
  • KRS Capital Management's Pacific Biosciences position peaked at $71K in Q4 2021.
  • 250 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2022.

Based on KRS Capital Management's 13F filing for Q1 2022, filed 27 Apr 2022.